Brief: Eiger Biopharmaceuticals Announces Peginterferon Lambda To Be Added To COVID-19 Study In Brazil
03/05/2021 13:58
May 3 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS ANNOUNCES PEGINTERFERON LAMBDA TO
BE
ADDED TO MULTI-CENTER PHASE 3 TOGETHER COVID-19 STUDY IN BRAZIL
Source text for Eikon: ID:nPn8dPYnTa
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview